| Today’s Big NewsApr 16, 2024 |
| By Kevin Dunleavy For the first time, Johnson & Johnson is reporting sales of its multiple myeloma drug Tecvayli, which is off to a strong launch and contributing to the company's overall strength in treating the disease. |
|
|
|
By Conor Hale After setting up more than $30 billion in medtech M&A spending within less than two years, Johnson & Johnson CEO Joaquin Duato said that trajectory will continue as the company looks to latch on to long-term growth. |
By Gabrielle Masson Takeda is offering Kumquat Biosciences the chance to make more than $1.2 billion biobucks in a new exclusive pact that centers around an unnamed immuno-oncology small molecule inhibitor. |
By Zoey Becker The company's late-stage pipeline focuses on oncology, cardiorespiratory diseases, mental health and cardiovascular-renal-metabolic conditions. Boehringer looks to kick off ten new phase 2 and 3 trials in the next 12-18 months, it said in its earnings release. |
|
Monday, April 22, 2024 | 10am ET / 7am PT Explore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now! 
|
|
By Andrea Park The drug’s name—pronounced way-NOO-ah—came about as part of a “lengthy, thoughtful process” between the two companies, according to Rachel Payne, global commercial VP of the ATTR team within AstraZeneca’s cardiovascular, renal and metabolism business. |
By Annalee Armstrong In a world overrun by innovative biotechs, be a Mammoth Biosciences. Or a Nutcracker Therapeutics. Or Viking Therapeutics or Centessa Pharmaceuticals. |
By Conor Hale The preliminary first-quarter earnings report is a dour departure from the high notes heard earlier this year after PacBio posted 56% annual growth following two new platform launches. |
By Angus Liu After getting a fat check worth $30.5 million for joining Biogen as the CEO in late 2022, Chris Viehbacher saw his 2023 pay drop to just $4.1 million as the Big Biotech continues struggling. |
By Andrea Park Mere weeks after earning the FDA’s signoff on new drug Winrevair to treat pulmonary arterial hypertension (PAH), Merck has kicked off an educational campaign around the rare disease. |
By James Waldron It’s not unusual to see a CD19-focused cancer company dip its toe into the autoimmune space these days, but Cullinan Oncology is going one stage further with a name change to reflect this new approach. |
By Gabrielle Masson,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
Fierce podcasts Don’t miss an episode |
| Using data from Fierce Biotech's layoff tracker, Gabrielle Masson and Max Bayer analyze the trends of layoffs in the first quarter of 2024, comparing them to previous years. |
|
|---|
|
|
|
Monday, April 29, 2024 | 12:30pm ET / 9:30am PTLearn how evolving healthcare delivery impacts product positioning for Integrated Delivery Networks. Discover key messages, stakeholders, and shifts in IDN perceptions post-COVID-19. Claim your spot. 
|
|
Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
eBook Unlock the future of mAb manufacturing with our complete guide to integrating the revolutionary Gibco™ Efficient-Pro™ Medium and Feeds System, enhancing productivity and quality for exceptional outcomes Sponsored by: Thermo Fisher Scientific |
Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
